The board of Bacil Pharma Limited has officially approved a new corporate capital mobilization strategy to raise up to ₹50 crore via a rights issue. The Mumbai-based firm will concurrently raise its total authorized share capital to ₹65 crore, establish a transaction steering committee, and transition its banking clearing functions to Axis Bank.
MUMBAI, India — Bacil Pharma Limited announced Thursday that its board of directors has formally authorized a capital mobilization plan to raise up to ₹50 crore via a rights issue of equity shares. The strategic decision, reached during a board session at the company’s corporate base in Andheri East, Mumbai, includes a substantial increase in authorized capital alongside an executive boardroom reconfiguration.
The announcement comes as pharmaceutical small-caps increasingly leverage primary equity market mechanisms to fortify liquid capital reserves and fund strategic balance sheet adjustments. For equity investors, the rights offering provides an structured avenue to preserve or expand ownership stakes ahead of the firm's next operational deployment cycle.
Technical Framework of the Bacil Pharma Rights Issue
In a compliance declaration delivered to BSE Limited, the management of Bacil Pharma Limited confirmed that the planned Bacil Pharma Rights Issue will consist of fresh equity shares aggregating up to a maximum value of ₹50,00,00,000. The equity issuance is structured under the legal parameters of the Companies Act, 2013, and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.
To accommodate the influx of new shares, the board simultaneously approved a structural expansion of its foundational capital ceiling. The resolution authorizes adding ₹45,00,00,000 to the existing capital pool, divided into 4,50,00,000 new equity shares carrying a face value of ₹10 each. This modification brings the total post-increase authorized share capital of Bacil Pharma Limited to ₹65,00,00,000, requiring a consequent amendment to the Capital Clause of the company’s Memorandum of Association (MOA) during an upcoming general meeting of shareholders.
Appointment of Key Intermediaries and Special Committee
To execute the financial transaction, the company has completed the structural appointment of legal and financial intermediaries:
Administrative control over the upcoming transaction has been concentrated within a newly formed, dedicated Rights Issue Committee. The panel is chaired by Mrs. Chaitali Kalpataru Shah, who simultaneously serves as the Executive Director and Chief Financial Officer (CFO) of the firm. Additional independent committee members include Vivek Mukesh Yadav and Omprakash Pyarelal Sonar.
Governance Adjustments and Compliance Mandates
Alongside the financial initiatives, Bacil Pharma experienced immediate shifts in its governance roster. The board accepted the formal resignations of Independent Directors Mr. Dinesh Chander Notiyal and Ms. Avani Savjibhai Godhaniya, who stepped down from their administrative positions on July 9, 2026.
In alignment with domestic insider trading laws under SEBI governance, the company’s internal compliance desk extended an existing trading window freeze. The restricted window bars all designated corporate insiders, key managerial personnel, and their immediate relatives from trading in Bacil Pharma securities, remaining firmly closed until 48 hours following the formal public dissemination of the board outcome.
Official Sources Section
The financial parameters and corporate appointments related to the Bacil Pharma Rights Issue were derived directly from official regulatory disclosures submitted on July 9, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The transaction documents were digitally signed and authorized by Chief Financial Officer Mrs. Chaitali Kalpataru Shah.
Quote Section
Regarding the implementation of the approved fundraising framework, organizers stated that:
"The detailed terms of the Rights Issue, including but not limited to the issue price, rights entitlement ratio, record date, timing, terms of payment, issue size, and other related matters, shall be determined by the Board of Directors or a duly constituted Committee thereof, in accordance with applicable laws, at the appropriate time."
Why It Matters
The deployment of the Bacil Pharma Rights Issue introduces practical market outcomes for various economic stakeholders:
For Existing Shareholders: The rights mechanism preserves investor equity weight by offering them first rights of refusal on new share classes, limiting arbitrary dilution by outside institutional groups.
For Corporate Capitalization: Elevating the authorized share limit to ₹65 crore creates systemic room for long-term capitalization, allowing the firm to quickly absorb strategic cash injections as operational requirements shift.
For Open Market Transparency: Utilizing an external monitoring agency like Acuite Ratings verifies that the capital generated from public markets is accurately deployed toward declared corporate objectives.
Key Facts at a Glance
Aggregate Issue Limit: The board locked the maximum fundraising target at ₹50,00,00,000.
Authorized Capital Peak: Total authorized capital climbs to ₹65 crore, pending formal retail shareholder assent.
Leadership of Committee: Executive Director and CFO Chaitali Kalpataru Shah will lead the specialized transaction committee.
Banking Partner: Financial operations will clear through Axis Bank's Sakinaka branch network.
Market Status: Securities are listed via BSE Scrip Code 524516.
FAQ Section
What is the primary purpose of the Bacil Pharma Rights Issue?
The capital exercise is designed to raise up to ₹50 crore in equity funding to enhance the overall financial resources and operational agility of the corporation.
Who is eligible to participate in this rights offering?
The Bacil Pharma Rights Issue will be offered exclusively to all eligible equity shareholders who hold company stock as of the official record date, which will be determined by the committee in a later communication.
How does the change in authorized share capital affect the company?
By adding ₹45 crore to its authorized capital pool, Bacil Pharma expands its maximum share issuance threshold, giving the company the necessary legal infrastructure to execute this and future equity updates.
Source: Official board meeting outcome disclosure issued by Bacil Pharma Limited, Company Disclosure to Stock Exchanges
